- Home
- PRT vs PLUR Comparison
PRT vs PLUR Comparison
Compare PRT & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | PLUR |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 33.9M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | PRT | PLUR |
|---|---|---|
| Price | $2.77 | $3.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 68.6K | 4.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $2.61 | $2.82 |
| 52 Week High | $4.28 | $6.10 |
Technical Indicators
Market Signals| Indicator | PRT | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 54.33 |
| Support Level | $2.75 | $3.14 |
| Resistance Level | $4.03 | $3.85 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 3.45 | 41.79 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.